Initially, the Impower130 study showed that no survival benefit was observed in the EGFR-mutant subgroup who received atezolizumab and carboplatin/nab-paclitaxel compared with those who received chemotherapy alone; however, the IMpower150 trial demonstrated that the addition of atezolizumab and bevacizumab to carboplatin/paclitaxel significantly improved PFS and OS in EGFR-mutated NSCLC patients, including those with previous TKI failures [112,113]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.